Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis

Peter Mollee, Giampaolo Merlini

Research output: Contribution to journalArticlepeer-review

Abstract

The disease causing agent in systemic AL amyloidosis is a monoclonal immunoglobulin free light chain, or fragments thereof, circulating in the blood. It is not surprising, therefore, that measurement of serum free light chains plays a central role in the management of this disorder. In this paper, we review the utility of the serum free light chain assay in the investigation, prognostication and monitoring of AL amyloidosis. Data on the two currently available commercial assays is compared and some practical applications of the assay's use are presented. While there are limitations, it is clear that the availability of the free light chain assay in the laboratory is a major advance and plays an essential role in the management of patients with AL amyloidosis.

Original languageEnglish
Pages (from-to)921-927
Number of pages7
JournalClinical Chemistry and Laboratory Medicine
Volume54
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Keywords

  • AL amyloidosis
  • free light chains
  • monitoring

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint

Dive into the research topics of 'Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis'. Together they form a unique fingerprint.

Cite this